Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) CAO Kristen Ambrose sold 327 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, April 25th. The stock was sold at an average price of $269.55, for a total transaction of $88,142.85. Following the completion of the sale, the chief accounting officer now directly owns 3,496 shares of the company’s stock, valued at approximately $942,346.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of VRTX stock opened at $267.25 on Thursday. The stock has a market cap of $68.29 billion, a P/E ratio of 29.60, a PEG ratio of 1.43 and a beta of 0.62. Vertex Pharmaceuticals Incorporated has a 52 week low of $176.36 and a 52 week high of $292.75. The company has a quick ratio of 4.30, a current ratio of 4.46 and a debt-to-equity ratio of 0.05. The company’s fifty day simple moving average is $255.72 and its two-hundred day simple moving average is $225.55.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last posted its earnings results on Wednesday, January 26th. The pharmaceutical company reported $3.18 earnings per share for the quarter, topping analysts’ consensus estimates of $2.91 by $0.27. Vertex Pharmaceuticals had a net margin of 30.92% and a return on equity of 32.33%. The firm had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $1.99 billion. During the same period in the previous year, the firm posted $2.22 EPS. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 12.7 EPS for the current fiscal year.
Several research analysts have recently weighed in on the stock. BMO Capital Markets upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $202.00 to $274.00 in a research note on Thursday, January 20th. HC Wainwright reiterated a “buy” rating and set a $275.00 price target on shares of Vertex Pharmaceuticals in a research note on Wednesday, March 23rd. Royal Bank of Canada cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $269.00 price target on the stock. in a research note on Thursday, February 3rd. Wells Fargo & Company lifted their price target on shares of Vertex Pharmaceuticals from $270.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 5th. Finally, Stifel Nicolaus lifted their price target on shares of Vertex Pharmaceuticals from $213.00 to $222.00 and gave the stock a “hold” rating in a research note on Thursday, January 27th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $271.43.
Vertex Pharmaceuticals Company Profile (Get Rating)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- Automatic Data Processing Is Ready To Scale New Heights
- Xerox Holdings Stock is a Value Play
- Carl Icahn Buys More Xerox
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.